StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) stock

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$16.11+0.12 (+0.75%)

Close on Nov 17, 2026Market cap $2.98BP/E –Yield –

Legend Biotech cash

Cash and short-term investments held at the end of each period.

Legend Biotech's cash was $672.90M at Jun 30, 2026. For fiscal 2025 it was $901.90M, up 214.6% from the year before. The highest annual figure on record is $1.28B in fiscal 2023.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$901.90M+214.6%
FY2024Dec 31, 2024$286.70M-77.6%
FY2023Dec 31, 2023$1.28B+62.6%
FY2022Dec 31, 2022$786.00M+14.1%
FY2021Dec 31, 2021$688.94M+51.2%
FY2020Dec 31, 2020$455.69M+446.6%
FY2019Dec 31, 2019$83.36M-60.3%
FY2018Dec 31, 2018$210.17M+9836.9%
FY2017Dec 31, 2017$2.12M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$672.90M+152.5%
Q1 FY2026Mar 31, 2026$646.40M+46.3%
Q4 FY2025Dec 31, 2025$901.90M+214.6%
Q3 FY2025Sep 30, 2025$278.89M-39.3%
Q2 FY2025Jun 30, 2025$266.50M+32.4%
Q1 FY2025Mar 31, 2025$441.70M-50.8%
Q4 FY2024Dec 31, 2024$286.70M-77.6%
Q3 FY2024Sep 30, 2024$459.28M-52.3%
Q2 FY2024Jun 30, 2024$201.25M-83.7%
Q1 FY2024Mar 31, 2024$897.57M+36.0%
Q4 FY2023Dec 31, 2023$1.28B+62.6%
Q3 FY2023Sep 30, 2023$963.47M+18.5%
Q2 FY2023Jun 30, 2023$1.23B+224.7%
Q1 FY2023Mar 31, 2023$660.05M-4.2%
Q4 FY2022Dec 31, 2022$786.00M+61.0%
Q3 FY2022Sep 30, 2022$812.73M+78.4%
Q2 FY2022Jun 30, 2022$379.78M-32.5%
Q4 FY2021Dec 31, 2021$688.94M+726.4%
Q2 FY2021Jun 30, 2021$488.22M+132.3%
Q4 FY2020Dec 31, 2020$455.69M+21445.6%
Q2 FY2020Jun 30, 2020$562.39M–
Q4 FY2019Dec 31, 2019$83.36M–
Q4 FY2018Dec 31, 2018$210.17M–
Q4 FY2017Dec 31, 2017$2.12M–

More Legend Biotech figures

See a number that looks wrong?